---
title: "Causal Multi‑modal AI (CTX) Stratifies Residual Risk and Predicts Everolimus Benefit in Node‑Posit"
id: "medrxiv-5-a-causal-multi-modal-ai-model-stratifies-residual-risk-and-identifies"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-5-a-causal-multi-modal-ai-model-stratifies-residual-risk-and-identifies"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.15.26362492v1?rss=1"
published_at: "2026-09-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Causal Multi‑modal AI (CTX) Stratifies Residual Risk and Predicts Everolimus Benefit in Node‑Posit
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-5-a-causal-multi-modal-ai-model-stratifies-residual-risk-and-identifies
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.15.26362492v1?rss=1)
- **Published At:** 2026-09-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This study evaluated **Ataraxis Breast CTX**, a causal multi‑modal AI model that integrates clinical variables and H&E histopathology image features to estimate residual recurrence risk and chemotherapy benefit in clinically defined high‑risk patients with node‑positive **HR+/HER2‑** early breast cancer. - CTX produces two outputs: **CTX‑prognostic** (estimate of recurrence risk) and **CTX‑benefit** (estimate of chemotherapy or escalation benefit). - A prospective‑retrospective validation was performed using patients from the phase III UNIRAD trial who did not receive neoadjuvant chemotherapy, received adjuvant chemotherapy, and had available H&E slides (n = 556). - The primary endpoint for this analysis was **disease‑free survival (DFS)**. - CTX‑prognostic stratified patients into low‑ and high‑risk groups: 5‑year DFS was 93% in the low‑risk group versus 80% in the high‑risk group across the cohort. - Exploratory multivariable analysis showed that **CTX‑benefit** significantly interacted with treatment assignment for benefit from adjuvant **everolimus** (interaction p = 0.01) after adjustment for age, tumor size, nodal status, grade, and menopausal status. - The authors conclude CTX can identify patients with excellent outcomes on **chemoendocrine** therapy alone and those with residual risk who may benefit from treatment escalation; CTX also showed predictive signal for everolimus benefit. - The analysis is based on a preprint (not peer reviewed). Data are not publicly available due to institutional and ethical constraints; access can be requested from Unicancer. - The UNIRAD trial (NCT01805271) was conducted under Good Clinical Practice and ethics approvals; the current analysis is retrospective and did not require further consent. Several authors hold equity in Ataraxis AI; other authors declared no competing interests.
## Clinical Analysis & Structured Key Points
A Causal Multi-modal AI Model Stratifies Residual Risk and Identifies Candidates for Treatment Escalation in Node-Positive HR+/HER2- Early Breast Cancer | medRxiv Skip to main content A Causal Multi-modal AI Model Stratifies Residual Risk and Identifies Candidates for Treatment Escalation in Node-Positive HR+/HER2- Early Breast Cancer Thomas Bachelot , Sylvie Chabaud , Jerome Lemonnier , Paul H. Cottu , Florence Dalenc , Frederick M. Howard , Lajos Pusztai , Cerise Tang , Dhruva Biswas , Ken Zeng , Jan Witowski , Krzysztof J. Geras , Fabrice Andre , Frederique Madeleine Penault-Llorca doi: https://doi.org/10.64898/2026.09.15.26362492 Thomas Bachelot 1 Medical Oncology Department, Centre Leon Berard, Lyon, France; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: thomas.bachelot{at}lyon.unicancer.fr Sylvie Chabaud 2 Department of Clinical Research and Innovation, Centre Leon Berard, Lyon, France; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jerome Lemonnier 3 Research and Development Unicancer, Paris, France; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Paul H. Cottu 4 Medical Oncology, Institut Curie, Universite, Paris, France; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Florence Dalenc 5 Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Frederick M. Howard 6 University of Chicago, Chicago, IL; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lajos Pusztai 7 Yale Cancer Center, New Haven, CT; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Cerise Tang 8 Ataraxis AI; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Dhruva Biswas 8 Ataraxis AI; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ken Zeng 8 Ataraxis AI; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jan Witowski 8 Ataraxis AI; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Krzysztof J. Geras 8 Ataraxis AI; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Fabrice Andre 9 Gustave Roussy and Paris-Saclay University, Villejuif, France; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Frederique Madeleine Penault-Llorca 10 Centre Jean Perrin, Universite Clermont Auvergne, INSERM, U1240 Imagerie Moleculaire et Strategies Theranostiques, Clermont-Ferrand, France Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Data/Code Preview PDF Abstract PURPOSE Prognostic biomarkers that estimate residual recurrence risk after standard adjuvant therapy to guide further treatment escalation are an unmet clinical need. This study used Ataraxis Breast CTX, a causal multi-modal AI model integrating clinical variables and histopathology, to stratify residual risk in clinically defined high-risk patients. We aimed to identify patients who have excellent outcomes on standard-of-care chemoendocrine therapy and patients who may benefit from additional therapies such as everolimus or CDK4/6 inhibitors. METHODS CTX combines clinical variables with image features from H&E images to produce estimates of recurrence risk (CTX-prognostic) and chemotherapy benefit (CTX-benefit). Prospective-retrospective validation was performed in the phase III UNIRAD trial to assess CTX-prognostic's performance in the subset of patients who had not received neoadjuvant chemotherapy, who had received adjuvant chemotherapy, and who had H&E slides available (n = 556). The primary endpoint in this study was disease-free survival (DFS). As an exploratory analysis, we evaluated CTX-benefit's ability to predict benefit from adjuvant everolimus. RESULTS CTX-prognostic effectively stratified patients into high- and low-risk groups. Across all patients, 5-year DFS was significantly higher in the low-risk group (93%) than in the high-risk group (80%). Additionally, treatment benefit from everolimus differed significantly by CTX-benefit score in an exploratory multivariable analysis adjusting for age, tumor size, nodal status, grade, and menopausal status (interaction p = 0.01). CONCLUSION CTX identified patients with good outcomes under chemoendocrine therapy alone and patients with residual risk who may benefit from treatment escalation. Additionally, CTX was found to be predictive of everolimus benefit. These results suggest that CTX may effectively stratify clinically high-risk HR+/HER2- patients by residual risk and may inform selection of adjuvant escalation strategies. Competing Interest Statement LP, CT, DB, KZ, KJG, and JW are equity holders of Ataraxis AI. All other authors declare no competing interests. Clinical Trial NCT01805271 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The UNIRAD trial ( NCT01805271 ) was conducted in accordance with Good Clinical Practice principles, the Declaration of Helsinki, and all local regulations. All patients provided written informed consent to participate in the trial and for data use. The trial was approved by the French medicines agency (ANSM-Agence National de Securite du medicament des produits de sante), by an ethics committee (Comite de Protection des Personnes Sud-Est IV-Lyon) in September 2012, and by institutional review boards of each participating center. A steering committee supervised the trial, and an independent data monitoring committee met every year and was responsible for monitoring safety and efficacy in the trial participants. As this re-analysis of the UNIRAD trial is retrospective in nature, no further informed consent was required. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data is not publicly available due to institutional and ethical constraints. Access can be requested directly from Unicancer. Funder Information Declared Ataraxis AI Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following A Causal Multi-modal AI Model Stratifies Residual Risk and Identifies Candidates for Treatment Escalation in Node-Positive HR+/HER2- Early Breast Cancer Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share A Causal Multi-modal AI Model Stratifies Residual Risk and Identifies Candidates for Treatment Escalation in Node-Positive HR+/HER2- Early Breast Cancer Thomas Bachelot , Sylvie Chabaud , Jerome Lemonnier , Paul H. Cottu , Florence Dalenc , Frederick M. Howard , Lajos Pusztai , Cerise Tang , Dhruva Biswas , Ken Zeng , Jan Witowski , Krzysztof J. Geras , Fabrice Andre , Frederique Madeleine Penault-Llorca medRxiv 2026.09.15.26362492; doi: https://doi.org/10.64898/2026.09.15.26362492 Share This Article: Copy Citation Tools A Causal Multi-modal AI Model Stratifies Residual Risk and Identifies Candidates for Treatment Escalation in Node-Positive HR+/HER2- Early Breast Cancer Thomas Bachelot , Sylvie Chabaud , Jerome Lemonnier , Paul H. Cottu , Florence Dalenc , Frederick M. Howard , Lajos Pusztai , Cerise Tang , Dhruva Biswas , Ken Zeng , Jan Witowski , Krzysztof J. Geras , Fabrice Andre , Frederique Madeleine Penault-Llorca medRxiv 2026.09.15.26362492; doi: https://doi.org/10.64898/2026.09.15.26362492 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Oncology Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (903) Anesthesia (335) Cardiovascular Medicine (4832) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1633) Epidemiology (15980) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7067) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5061) Health Policy (1438) Health Systems and Quality Improvement (1776) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16310) Intensive Care and Critical Care Medicine (1176) Medical Education (671) Medical Ethics (155) Nephrology (727) Neurology (7294) Nursing (369) Nutrition (1084) Obstetrics and Gynecology (1244) Occupational and Environmental Health (1006) Oncology (3617) Ophthalmology (1055) Orthopedics (398) Otolaryngology (458) Pain Medicine (474) Palliative Medicine (140) Pathology (709) Pediatrics (1805) Pharmacology and Therapeutics (739) Primary Care Research (769) Psychiatry and Clinical Psychology (5921) Public and Global Health (9772) Radiology and Imaging (2433) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (643) Sexual and Reproductive Health (773) Sports Medicine (581) Surgery (783) Toxicology (107) Transplantation (305) Urology (293)
## Related Clinical Research

- [Structured aerobic exercise linked to lower cancer recurrence and improved survival](https://medichelpline.com/clinical-feed/medical-news-today-0-aerobic-exercise-could-help-improve-outlook-after-cancer-treatment.md)
- [Inflammatory Biomarkers and Risk of Postmenopausal ER-Positive Breast Cancer](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-inflammatory-biomarkers-and-risk-of-postmenopausal-oestrogen-receptor-positive.md)
- [Educating Patients on ‘Asian Glow’ and Alcohol Risks in East Asian Populations](https://medichelpline.com/clinical-feed/stat-news-0-opinion-doctors-should-educate-patients-about-asian-glow-and-drinking-risks.md)
- [Federated Learning and In-House Dashboards for Data Quality Assurance in Multi‑Center Oncology Data](https://medichelpline.com/clinical-feed/medrxiv-14-data-auditing-and-quality-assurance-in-a-federated-learning-consortium-getting.md)
- [Sellas Phase 3 REGAL trial for galinpepimut-S faces delays and likely negative outcome in AML](https://medichelpline.com/clinical-feed/stat-news-1-stat-a-sellas-immunotherapy-study-long-delayed-will-end-in-failure.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.